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ABSTRACT
The purpose of these studies was to explore the roles of dietary strategies and bariatric
surgery in obesity treatment. The breakfast study was a randomized, crossover trial used to
evaluate the role of egg proteins, and a retrospective chart review was conducted to obtain
comparative information about two different bariatric surgeries.
The breakfast study included 20 subjects who were randomized to receive an egg
breakfast (EB) or a cereal breakfast (CB) matched for energy density and macronutrient
composition but different protein quality for one week. Following a washout period, each subject
was crossed over to receive the opposite breakfast for one week. The EB resulted in lower
cumulative lunchtime food intake (p=0.05), reduced hunger on day 1 (p=0.001), greater feelings
of fullness on days 1 and 7 (p=0.02), and decreased desire to eat on day 1 (p=0.03). Acylated
ghrelin was lower on day 1 of the EB compared to the CB (p=0.005) but not on day 7. PYY was
greater at 120 minutes (p=0.006) and 180 minutes (p=0.001) on day 1 and at 180 minutes on day
7 (p=0.03) after the EB.
The bariatric surgery studies examined 835 Roux-en-Y gastric bypass (RYGB) patients
and 766 vertical sleeve gastrectomy (VSG) patients. Study one focused on patients diagnosed
with type 2 diabetes (T2D). The acute effect bariatric surgery had on resolving T2D was
measured by calculating the number of patients who discontinued their hypoglycemic medication
use post-operatively. Upon discharge, 95 of the 123 (77.2%) RYGB patients and 107 of the 139
(77.0%) VSG patients had been taken off their medication. Eight weeks post-operatively, 30 of
the 38 (~79%) RYGB patients and 59 of the 71 (83%) VSG patients with follow-up data
remained off medication. Study two examined differences in weight loss, early post-operative
surgical complications, and insurance coverage between RYGB and VSG patients. RYGB
v

patients lost more weight at one and two years (p<0.001 for both). There was no significant
difference in the percentage of weight loss or complications in insured versus self-pay patients.
RYGB patients experienced a higher incidence of major complications than VSG patients
(p<0.001).
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CHAPTER 1
INTRODUCTION
When energy intake exceeds energy expenditure, the positive energy balance leads to the
storage of excess energy as fat1. The abundance of food in the current environment combined
with increasingly sedentary lifestyles contributes to positive energy balance1. Genetics also play
a role in body fat regulation1. The genetic makeup of modern man has not significantly changed
since the era of the hunter-gather society1, 2. During that time, humans ate copiously when food
was abundant and were able to store excess energy as fat for times when food was unavailable1.
This genetic predisposition to store fat combined with behavioral and environmental factors may
explain why many individuals are growing obese.
Obesity, a disease of excess energy stored as adipose1, 3, has become an epidemic in the
US 4, 5. Approximately 1/3 of the adult population is considered obese6. The World Health
Organization (WHO) divides obese individuals into three classes: class I (BMI = 30-34.9 kg/m2),
class II (BMI = 35.0-39.9 kg/m2), and class III (BMI > 40 kg/m2)7, 8. Individuals within class III
are morbidly obese which indicates they are at least 100 pounds overweight3. If current obesity
trends continue, data from the National Health and Nutrition Examination Study (NHANES)
project that 51.1% of all adults in the US will be obese by 20305, and global projections surpass
one billion people by 20309.
Not only is obesity linked to a harsh social stigma10, but it is also linked to many comorbid conditions such as cardiovascular disease11, 12, hypertension11-13, diabetes11, 12, obstructive
sleep apnea11-13, certain cancers12, and degenerative joint disease3, 12, 13. According to one
prospective study of over 4500 obese patients, the most common co-morbidities were
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hypertension (55.1%), obstructive sleep apnea (48.9%), diabetes (33.2%), and asthma (23.1%)14.
More than 50% of these patients had at least two co-morbid conditions14. Even without any
existing co-morbid conditions, obesity increases the risk of mortality15. In 2000, approximately
360,000 deaths were obesity-related11. Because obesity increases the risk of other diseases,
healthcare costs for obese individuals exceed those of normal weight individuals16. In 2008,
obesity-associated medical costs were estimated to be $147 billion dollars16 and are projected to
reach $960 billion dollars in the next two decades5.
The World Health Organization (WHO) and National Institutes of Health (NIH) clinical
guidelines for obesity suggest obese individuals should reduce their energy intake and increase
their energy expenditure to induce a 10% weight loss17, 18. Diets of different macronutrient
compositions have been found to result in similar weight loss of 7% after 6 months19, and a diet
that follows a 25% caloric restriction has been shown to result in a 10% weight loss at 24
weeks20. Dietary strategies that decrease hunger and increase satiety may be useful for
individuals following a reduced-energy diet. Holt et al21 tested the effect of several foods on their
ability to induce satiety and found that eggs have twice as much satiety-inducing capability as
ready-to-eat breakfast cereals22. Eating a daily breakfast, especially one that is high in protein,
has been shown to reduce ghrelin23, increase peptide YY24, and reduce energy intake for the
remainder of the day25. Thus, eating high-protein foods such as eggs for breakfast may enhance
weight loss.
Engaging in physical activity can increase energy expenditure and lead to a reduction in
weight and body fat26. Exercise also plays a role in the prevention of weight gain26.
Pharmacologic agents such as orlistat can be used in combination with lifestyle modifications to
augment weight loss and aid in weight loss maintenance27. However, of all the obesity treatment
2

alternatives available, bariatric surgery is the most effective treatment for morbid obesity8, 28.
Numerous studies have found that clinically significant weight loss can be achieved through
bariatric surgery within one to two years and can be maintained over time29. If attempts to lose
weight through diet, exercise, and obesity drugs fail, individuals may seek bariatric surgery to
lose weight and to improve or resolve any co-morbidities.
Justification
Because obesity currently affects 1/3 of the US adult population, and the number of obese
adolescents and children is also increasing, obesity treatment alternatives need to be examined
for their effectiveness in inducing and maintaining weight loss. Dietary approaches to obesity
may be the safest method for weight management, but few studies show diets that result in
significant maintenance of weight loss. Dietary strategies for weight loss that individuals can
easily follow over time are needed. Bariatric surgery appears to result in significant weight loss,
but most studies focus on the more established gastric bypass. Few studies examine large
samples of a newer bariatric operation, the vertical sleeve gastrectomy.
Research Questions
1. Does protein quality affect food intake and satiety in overweight adults?
2. Does the vertical sleeve gastrectomy resolve diabetes as effectively as the Roux-en-Y
gastric bypass?
3. Does the vertical sleeve gastrectomy result in similar weight loss to the Roux-en-Y
gastric bypass?
4. Does the vertical sleeve gastrectomy result in fewer or greater complications than the
Roux-en-Y gastric bypass?
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5. Does payment method (i.e. insurance or self-pay) influence weight loss in vertical sleeve
gastrectomy patients and Roux-en-Y gastric bypass patients?
Objectives
1. To determine if consuming a breakfast with high quality protein is associated with
increased satiety and decreased food and energy intake at lunch.
2. To determine if the vertical sleeve gastrectomy is as effective as the Roux-en-Y gastric
bypass in resolving diabetes.
3. To determine if the vertical sleeve gastrectomy results in similar weight loss with a
similar or lower complication rate than the Roux-en-Y gastric bypass and if insurance
reimbursement affects weight loss.

Hypothesis
1. A breakfast containing greater protein quality will decrease food intake and increase
satiety in overweight adults more than a breakfast with lower protein quality.
Limitations
1. The breakfast study did not measure GLP-1 following breakfast or lunch.
2. The breakfast study had a small sample size (n=20).
3. The breakfast study only showed an acute effect of each breakfast.
4. The bariatric surgery studies were based upon information from a retrospective chart
review.
5. The bariatric charts had limited follow up so long-term results were not obtained.
6. The bariatric charts lacked laboratory data to show changes in glucose, insulin,
cholesterol and triglyceride levels, and vitamin levels.
4

Assumptions
1. The information contained in the bariatric charts was accurate and reliable.
Definitions
1. National Health and Nutrition Examination Survey (NHANES): a continuous program
that collects information about the nutrition and health status of the US population using
a complex, multi-stage probability sampling design
2. Body Mass Index (BMI): body weight (kg) divided by height (m2) used as a measurement
to classify weight status
3. Obesity: BMI > 30 kg/m2
4. Morbid obesity: BMI > 40 kg/m2
5. Satiety index score (SIS): score that measures a food’s satiating capabilities
6. Branched chain amino acid (BCAA): amino acids with an aliphatic side chain; include
the amino acids leucine, isoleucine, and valine
7. Jejuno-ileal bypass (JIB): one of the first bariatric procedures used to induce weight loss
but was discontinued because it resulted in severe complications
8. Roux-en-Y gastric bypass (RYGB): a bariatric procedure involving the creation of a
small gastric pouch combined with a gastrointestinal bypass which excludes the
duodenum and the proximal jejunum
9. Vertical sleeve gastrectomy (VSG): a bariatric procedure involving a subtotal gastric
resection of the fundus and body to create a long, tubular gastric conduit along the lesser
curve of the stomach
10. National Institutes of Health (NIH): the medical research agency of the United States
11. World Health Organization (WHO): the authority for health within the United Nations
system which manages global health issues and the health research agenda
5

12. Excess weight: mid-point in the range of ideal body weight as defined by the 1983
Metropolitan Life Insurance Tables for a medium frame subtracted from initial weight
13. Excess weight loss (EWL): [Weight loss (lbs)/Excess weight (lbs)]*100
14. Type 2 diabetes (T2D): chronic disease in which blood glucose levels are elevated as a
result of insulin resistance with or without a defect in insulin secretion by the pancreatic
beta cells
15. Homeostatic Model Assessment (HOMA): model used to quantify insulin resistance and
beta-cell function
16. American Society for Metabolic and Bariatric Surgery (ASMBS): society created to
advance the science of bariatric surgery whose goal is to improve the treatment of obesity
and obesity-related diseases through the understanding of metabolic surgery
17. Glucagon-like peptide 1 (GLP-1): peptide hormone produced by the L cells which is
released in response to meal intake and may act as physiological regulator of food intake
by suppressing appetite after the consumption of food
18. Peptide YY (PYY): peptide hormone produced by the L cells which is released in
response to meal intake and may act as physiological regulator of food intake by
suppressing appetite after the consumption of food
19. Acylated ghrelin: orexigenic hormone secreted primarily in the stomach which plays a
role in appetite regulation by inducing hunger
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CHAPTER 2
REVIEW OF LITERATURE
Obesity has become a nationwide epidemic over the past few decades5, 13, 30, 31. No state
had a prevalence of obesity greater than 15% in 1990, but only two decades later in 2010, no
state had a prevalence less than 20%30. Currently, 36 states have an obesity prevalence greater
than or equal to 25%30. The morbidly obese population doubled between 2000 and 200511, and
data from the 2007-2008 National Health and Nutrition Examination Survey (NHANES) has
shown that 33.8% of the United States (US) adult population is obese32.
Weight is affected by a combination of genetic, behavioral, and environmental factors33.
Behavioral factors include diet composition and exercise, and environmental factors include
where a person lives, works, and socializes33. Although genetics do play a role in some obesityrelated diseases, the human genome has not changed enough to completely explain the rise in
obesity33. The “thrifty gene” hypothesis states that the body’s process of storing calories as fat
during abundance in the days of early humans may now be working to our disadvantage34. Food
is now readily available, and current lifestyles are more sedentary and less labor-intensive
compared to the hunter-gatherer era2. In addition, when the amount of adipose tissues changes,
the body’s desire to maintain energy homeostasis resists weight change31. Thus, the lifestyle
followed by many individuals leads to a positive energy balance in which more calories are
consumed than expended on a daily basis.
Because obesity increases the risk of co-morbidities and mortality, effective strategies
should be utilized to induce weight loss. Currently, obesity treatment options include diet,
exercise, behavioral modification, anorectic drugs, and bariatric surgery27, 35. Non-surgical
approaches to obesity typically result in minimal weight loss, and over long periods of time, may
7

result in weight regain15, 28. However, many individuals attempt to lose weight through diet and
exercise26, 36 before undergoing more drastic measures such as bariatric surgery. Also,
individuals must be morbidly obese to be clinically eligible to undergo bariatric surgery. A study
that examined weight loss diets in over 800 subjects showed that all the diets produced an
average weight loss of four kilograms after two years regardless of macronutrient composition19.
Thus, calorie restriction appears to be the most important factor for dieting and not macronutrient
composition19, 27. A study examining the chronic effect of caloric restriction showed that a diet
that restricted normal caloric intake by 25% resulted in ~10% weight loss at 24 weeks20.
However, adherence to a low kilocalorie diet can be difficult to maintain over time so using
dietary strategies that decrease hunger and increase satiety may improve weight loss efforts37, 38.
One easily adaptable strategy that may improve weight loss efforts is to eat a daily
breakfast39. Body mass index (BMI) and breakfast consumption are negatively correlated40.
Although breakfast eaters have been shown to have a higher daily energy intake, they have been
shown to have lower BMIs than breakfast skippers40-42. Because breakfasts differing in
macronutrient composition have not been shown to affect lunchtime energy intake differently43,
individuals should consider consuming breakfast foods known to increase satiety. Eggs, a
common breakfast food, have been found to have a 50% greater satiety index scores (SIS) than
ready-to-eat cereal21. Eggs have been shown to increase satiety and decrease lunchtime energy
intake22. When individuals ate eggs daily for breakfast in addition to following a reduced calorie
diet, they reduced their BMI and waist circumference more than individuals who ate an
isocaloric bagel breakfast37. They also displayed greater dietary restraint and had greater
reductions in hunger than bagel breakfast eaters37. In contrast, cross-sectional data from
NHANES has shown that individuals who consume ready-to-eat cereals have lower BMIs than
8

meat and egg breakfast eaters40. However, these results may indicate that eating eggs can be a
marker of other dietary indiscretions. Thus, including eggs as part of a daily breakfast may
induce greater results in a weight loss regimen.
High-protein diets appear to result in greater reductions in weight because protein
increases satiety and thermogenesis, reduces loss of lean body mass, and promotes body fat loss,
and improves glycemic control44. Individuals who increased their protein intake at breakfast had
decreased postprandial ghrelin concentrations23 and thus decreased hunger23, 45. Increased intake
of protein, especially higher quality proteins, has been shown to enhance weight loss44, 46, 47.
Consuming more protein also leads to an increased intake of the branched chain amino acid
(BCAA) leucine46. The satiating effect of eggs may possibly be due to the high quality of egg
proteins which are rich in leucine and has been implicated in inducing satiety44, 47, 48. Leucine
promotes protein synthesis and regulates insulin release and signaling49. A study by Layman et
al46 compared a moderate protein diet and a high carbohydrate diet with different amounts of
leucine (9.89±0.19 g and 5.39±0.10 g, respectively) over a 10-week period. Subjects in the
protein group lost more weight and body fat but less lean body mass than the carbohydrate group
although the differences were not significant46. However, this suggests that leucine acts as a
metabolic regulator, and through its actions in insulin and glucose, can preserve lean muscle
while reducing body fat.
Several drugs have been developed to treat obesity through weight reduction50. Orlistat
prevents ~30% of fat absorption when taken with a meal27, but it only produces an average
weight loss of 2.9 kg at 12 months27, 50. Anti-obesity drugs such as rimonabant and sibutramine
produced a weight loss between 3-5 kilograms in six months to one year, but they have been
withdrawn from the market due to adverse side effects27, 50. Because few anorectic drugs are
9

available on the market, and many people struggle to lose a clinically significant amount of
weight through diet and exercise, they may elect to undergo bariatric surgery.
The first bariatric operation, the jejuno-ileal bypass (JIB), was performed in 1954;
however, it resulted in severe complications including hepatic and renal failure51. Several years
later, Dr. Edward Mason’s observations led to the development of the gastric bypass, an
operation that resulted in significant weight loss but less severe complications than the JIB52. In
1994, Wittgrove and Clark introduced the laparoscopic technique for the gastric bypass which
has been shown to have certain advantages over the previously used open method28, 51. Surgeons
conduct a Roux-en-Y gastric bypass (RYGB) by first creating a small gastric pouch 20-30
milliliters in volume. The duodenum and proximal jejunum are bypassed, and a Roux limb 75105 centimeters long reroutes the distal jejunum and ileum to the pouch11. The RYGB is a
restrictive and malabsorptive procedure that induces weight loss through a combination of food
restriction and malabsorption51.
The vertical sleeve gastrectomy (VSG), a much newer bariatric operation, was originally
the first step in the biliopancreatic diversion with duodenal switch13, 53, 54. To decrease the risk of
surgical complications and mortality in super obese individuals, individuals would first undergo
the sleeve gastrectomy which was later followed by a second step13, 55. However, the weight loss
and co-morbidity resolution achieved with the VSG alone has prompted the use of the VSG as a
primary procedure13, 55. The sleeve gastrectomy entails a resection of the greater curvature of the
stomach which creates a tubular stomach and preserves the pylorus and part of the antrum11.
The VSG is a restrictive procedure that induces weight loss through the restriction of food
intake51. Because part of the stomach is removed, gut hormones are also affected and may be a
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potential mechanism aiding in weight loss56. Currently, the VSG accounts for less than 5% of all
bariatric procedures in the US53, 57.
The number of bariatric operations performed annually increased 900% between 1998
and 200458. In spite of this significant increase, only 1% of clinically eligible patients undergo a
bariatric operation each year11. According to criteria established by the National Institutes of
Health (NIH), an individual must be morbidly obese (BMI > 40 kg/m2) or have a BMI > 35
kg/m2 with a serious co-morbid condition such as cardiopulmonary disease or diabetes to be
eligible for a bariatric operation35. Today, the laparoscopic gastric bypass comprises the majority
of bariatric operations in the US14, 59.
Bariatric surgery appeals to morbidly obese individuals because it has been shown to
result in clinically significant, sustainable weight loss. The average BMI for individuals electing
to have bariatric surgery is greater than 40 kg/m2 60-62. The RYGB has been shown to result in an
average excess weight loss (EWL) of 50.2±6.5% at six months post-operatively56, and has
reached ~70% at one year56, 62. One long-term study showed that RYGB patients can maintain an
EWL of 49% 14 years post-operatively29. Similarly, the VSG has resulted in an average excess
weight loss ranging from ~39% to ~56% at six months56, 63, 49% to ~70% at one year56, 62, 63, and
~68% at two years post-operatively64. Average excess BMI loss one year post-operatively for the
RYGB and VSG is 70.1% and 55.3%, respectively65. Currently, limited data exists in the
literature describing long-term weight loss produced by the VSG66.
Bariatric surgery also has also been shown to improve or resolve co-morbid conditions
such as diabetes significantly more than non-surgical options67, 68. Several studies comparing the
RYGB and VSG demonstrated that both surgeries comparably resolve hypertension,
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dyslipidemia, obstructive sleep apnea, and type 2 diabetes (T2D)69. One prospective study that
followed 608 morbidly obese patients for 14 years after gastric bypass surgery showed surgery is
the most effective treatment for maintaining normal plasma glucose concentrations in individuals
with T2D or impaired glucose tolerance29. Although diabetic medications help control blood
glucose levels, they may not prevent the progression of the disease which leads to microvascular
complications including retinopathy, nephropathy, and neuropathy. T2D may also lead to
cardiovascular disease which accounts for 70% of the deaths in individuals with T2D in the
US68.
The VSG has similar efficacy to the RYGB in T2D remission70, 71. The RYGB and VSG
resolved T2D in approximately 85% of subjects (n=91) in one study at one year postoperatively70, and a study comparing the VSG and RYGB in 90 patients found no significant
differences in diabetes control between the two operations at one and two years71. Both surgeries
appear to result in early, dramatic improvements in glycemic control and Homeostatic Model
Assessment (HOMA) indices that are maintained post-operatively72. However, conflicting ideas
remain on the efficacy of the VSG because the proximal small intestines are not excluded72, 73.
Lee et al demonstrated greater T2D resolution in RYGB patients compared to VSG patients at 12
months (93% and 47%, respectively) which they attributed to the exclusion of the duodenum73.
In contrast, Nocca et al found that more VSG patients discontinued taking diabetic medication
than RYGB patients74. Bariatric surgery can also effectively improve or resolve many other
conditions in the majority of patients55, 61, 69, 75, 76, and it can also decrease the risk of mortality by
35% compared to morbidly obese individuals who do not undergo obesity surgery14, 15.
Studies have shown low overall mortality rates following bariatric surgery ranging from
0.1% to 1.5%57, 59, 77. Thirty-day mortality rates appeared to be less than 0.2% for all bariatric
12

operations57, 59, and less than 2% specifically for RYGB78. The mortality rate for VSG patients
appears to be less than 1%12, 13, 79. According to data of over 66,000 surgeries from the American
Society for Metabolic and Bariatric Surgery (ASMBS) Centers of Excellence, the three
predominant causes of mortality were pulmonary emboli, cardiac complications, and
sepsis/infection59.
Common minor complications identified by the ASMBS include atelectasis, dehydration,
diarrhea, dumping syndrome, esophageal reflux, pneumonia, nausea and vomiting, and
infection80, 81. Common major complications include cardiopulmonary issues such as cardiac
arrest, deep venous thrombosis, pulmonary embolism and respiratory arrest or failure,
gastrointestinal (GI) bleeds or leaks, small bowel obstruction, anastomotic stricture, ulcer at the
anastomosis or in the GI tract, and wound dehiscence or infection80, 81. Complications
experienced by patients appear to be dependent on the type of surgery and the surgeon’s
experience78. A review of 3,464 gastric bypass cases found wound infections, anastomotic leaks,
gastrointestinal tract hemorrhages, bowel obstructions, and pulmonary emboli were the most
common complications occurring in the early post-operative period82. Studies report differing
overall total complication rates in RYGB patients. Sjostrom et al83 and Carrodeguas et al84
reported a complication rate of 13% in 1164 patients and 31% in 1291 patients, respectively, as
well as differing major complications. Complication rates vary in VSG patients and range from
0% to 23.8%66. The most common complications patients encounter with the VSG appear to be
gastrointestinal bleeds13, 66 and gastrointestinal leaks12, 13, 66.
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Journal Articles
Of the three articles presented as part of this thesis, one has been published, one is under
review, and the other is soon to be submitted. The objective of the egg breakfast article was to
determine whether high protein quality eaten at breakfast affects satiety and food intake at lunch.
The objective of the two articles on bariatric surgery was to compare the vertical sleeve
gastrectomy to the Roux-en-Y gastric bypass in terms of weight loss, diabetes resolution, the
incidence of major and minor complications, and the effect of insurance coverage on weight loss
and complications.
The first article, “Superior Quality of Egg Protein Results in Increased Satiety,”
compared the effect an egg breakfast containing high quality protein had on satiety and food
intake compared to a ready-to-eat cereal breakfast matched for energy density and macronutrient
composition. It has been submitted to the American Journal of Clinical Nutrition. Bayham et al
found that the egg breakfast reduced cumulative lunchtime intake, decreased acylated ghrelin
post-breakfast, and increased PYY post-breakfast. The egg breakfast also improved the HOMA
index in individuals who had greater insulin resistance prior to the study.
The second article entitled “Early Resolution of Type 2 Diabetes Seen after Roux-en-Y
Gastric Bypass and Vertical Sleeve Gastrectomy” has been published in Diabetes Technology
and Therapeutics. Bayham et al found that both operations equally resolved T2D in obese adults,
but the vertical sleeve gastrectomy had a significantly lower rate of overall complications in
individuals with T2D. At eight-weeks post-operatively, approximately 79% of RYGB and 83%
of VSG patients remained off their diabetes medication.
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A third article, “Sleeve Gastrectomy Results in Less Weight Loss but Fewer Major
Complications than the Roux-en-Y Gastric Bypass” will be submitted to the Annals of Family
Medicine. Bayham et al found that the RYGB resulted in greater weight loss at one and two
years than the VSG, but the VSG resulted in fewer major complications than the RYGB.
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CHAPTER 3
BREAKFAST CONTAINING EGG PROTEINS INDUCES GREATER SATIETY
COMPARED TO A BREAKFAST WITH LOWER PROTEIN QUALITY
Data from the 2007-2008 National Health and Nutrition Examination Survey (NHANES)
showed that 68% of adults in the United States (US) are overweight or obese32. Consuming less
energy than needed for weight maintenance is the cornerstone of weight loss treatment.
However, long-term compliance following a reduced energy diet is challenging85. Hence,
additional supportive strategies are needed. Researchers are currently investigating nutritional
approaches to reduce food intake. Foods differ in their ability to reduce hunger and increase
satiety21. Breakfast foods with high satiety index scores (SIS) induce a greater feeling of fullness
compared to those with lower SIS and are also negatively correlated with energy intake at
lunch85. Therefore, higher SIS breakfasts may help in reducing food intake during a day.
Eggs, a common breakfast food, have a 50% greater SIS than ready-to-eat (RTE) cereal21.
An egg breakfast (EB) results in greater feelings of satiety and decreased energy intake at
lunch22. When habitual EB eaters follow a reduced calorie diet, they reduce their BMI more than
those who eat an isocaloric bagel breakfast37.
Incorporating eggs in the diet may supplement weight loss efforts by inducing satiety and
increasing compliance with a reduced-calorie diet. Eggs are protein-rich and contain high
concentrations of the branched-chain amino acid (BCAA) leucine44. Leucine plays a role in
insulin signaling and glucose metabolism44, 86, and it has been shown to decrease food intake and
body weight48. A mouse model of diet-induced obesity demonstrated that increasing dietary
leucine reduces inflammation in the adipose tissue and improves glucose tolerance when
consuming a high-fat diet87. Previous studies that compared the effects of an EB to a bagel
breakfast did not match them for macronutrient composition, and the EB had a greater amount of
16

protein22, 37. It was unclear if the satiating effect of the EB was due to greater protein quantity or
the better quality of egg proteins.
Here we tested the hypothesis that an EB will induce greater satiety than a RTE wheat
cereal breakfast (CB) with lower protein quality but similar energy density (ED) and
macronutrient composition. Thus, by matching the protein quantity, we determined if the
breakfast containing higher quality protein increased satiety and reduce food intake. The
satiating effects of the breakfasts was assessed at the beginning and end of two, one-week
periods by hunger and satiety ratings from questionnaires, food intake at lunch, and satiety
hormone concentrations. Secondarily, we determined changes in indices of glycemic control in
response to EB and CB consumption.
Methods
This study was approved by the institutional review board at Pennington Biomedical
Research Center. Written informed consent was obtained from the subjects prior to the initiation
of study procedures.
Eligibility Criteria
Individuals were screened over the telephone to determine their eligibility including
having a BMI > 25 and < 60 kg/m2, being between 18 and 60 years of age, and having lost no
more than 5% body weight in the three months preceding the study. Those who qualified came to
the clinic for a screening visit which included a history and physical examination to determine
eligibility. Individuals with an unstable cardiac condition; major systemic illness; history of drug
abuse or eating disorder; uncontrolled diabetes or hypothyroidism; familial hyperlipidemia; an
allergy, sensitivity, or dislike of eggs, soy, or wheat; those attempting to lose weight; or those
with an eating disorder were excluded from the study.
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Subjects
Of the 56 subjects who screened for the study, 20 meet eligibility criteria to enter the
intervention trial. Subjects were randomized into two groups. One subject withdrew from the
study and was subsequently replaced. The data collected for the withdrawn subject was
discarded. Group 1 consumed the EB during the first test week and the CB during the second test
week, and group 2 consumed the CB during the first test week and the EB during the second test
week. Subjects completed the study on individual timelines and were not assessed as groups.
Procedures
In this randomized, crossover trial, each subject received two diets in random order. Nine
subjects were randomized to receive the EB, and 11 subjects were randomized to receive the CB
during the first test week. On day one, subjects reported to the clinic following a 12-hour fast and
were provided with breakfast at 8:00 AM which they were required to consume completely. The
EB was similar to the CB in weight (g), caloric content, and macronutrient composition
(described below and in Table 1). An intravenous line was placed in each subject’s forearm
before breakfast to collect blood samples until 120 minutes after consuming lunch. Subjects
remained in the clinic and were given a standardized lunch 180 minutes after they consumed
breakfast. A questionnaire assessed their satiety and hunger before and after breakfast and lunch
(described below). To avoid unintentional impact on food intake, the subjects were told the
purported aim of the study was to determine the effect of breakfast on blood glucose and insulin,
blood hormones and blood pressure. Subjects came to the clinic for the next six days at 8:00 AM
in a fasting state to eat the same breakfast consumed on day one. No blood samples were
collected and lunch was not provided on days 2-6. On day seven, the blood tests and
questionnaires were repeated and food and water intake were measured following lunch. After
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the first test week, the subjects underwent a two-week washout period in which they consumed
their usual pre-study breakfasts. Following the washout period, they returned for the second test
week, and the cycle was repeated with the opposite breakfast.
Breakfast and Lunch
The EB contained two scrambled eggs, 120 ml skim milk, two slices of Holsum® thin
white bread, 5 g of butter, and 18 g of Smuckers® strawberry jam. The CB contained 1.5 cups of
Special K® ready-to-eat cereal, 200 ml Silk® original soymilk, one slice of Natural Grain
“Wheat n’ Fiber”® bread, 13 g of butter, and 10 g of sugar-free strawberry jam. The breakfasts
were matched for ED and macronutrient composition but differed in the Protein Digestibility
Corrected Amino Acid Score (PDCAAS)88, leucine content, and glycemic load (Table 1). A
standardized lunch consisting of lemon sage chicken, wild rice, mixed vegetables, a white dinner
roll, canned pears, salted butter, 1% milk, and water was provided ad libitum. The amount of
food and water consumed was covertly weighed both before and after the subject was served.
Table 1. Energy density, macronutrient composition, and protein score of the breakfasts
Egg breakfast
Wheat breakfast
Weight (g)
291
293
Energy (kcal)
400
398
Energy density (kcal/g)
1.37
1.36
Carbohydrate (%)
43.1
44.8
Fat (%)
36.0
35.4
Protein (%)
20.2
19.8
Protein (g)
12.5
13.7
PDCAAS1
100
42
Leucine (g)
1.77
0.48
Glycemic load
24
30.8
1
Protein Digestibility Corrected Amino Acid Score
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Measures
Demographic characteristics – Age, race, and sex were self-reported. Height and
weight were measured with light clothing and no shoes during the screening visit prior to the
initiation of study procedures. BMI was calculated as kg/m2 89. Weight was also measured on
days one and seven of each test week.

Blood chemistry – Blood samples were taken from the subject in a fasting state before
breakfast was consumed (0 minutes) and were subsequently analyzed to determine fasting serum
glucose, serum insulin, peptide YY (PYY), acylated ghrelin, and serum leucine. The
Homeostatic Model Assessment (HOMA) index of insulin resistance was calculated as
previously described90 using fasting glucose and insulin levels. Blood samples were also taken
30, 60, 120, and 180 minutes after breakfast and 120 minutes after lunch to repeat the
assessments of the satiety-related hormones, PYY and acylated ghrelin. To assess serum leucine
concentrations, blood samples were taken 60 and 300 minutes after breakfast.

Questionnaire – A visual analog scale (VAS) was used to measure hunger and satiety as
previously described91. It consisted of lines which subjects were asked to mark corresponding to
their feelings for each question from 0 (not at all) to 100 (most imaginable). The following
questions were given to the participants using questionnaires presented electronically before and
after breakfast and lunch: 1) How hungry do you feel at this moment?, 2) How full does your
stomach feel at this moment?, 3) How strong is your desire to eat at this moment?, 4) How much
food do you think you could eat at this moment?, and 5) How satisfied do you feel at this
moment?
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Statistics
Data were summarized as counts and percents for categorical variables and as means and
standard deviations for continuous variables. Student’s t-test was employed to assess the
significance of the difference between EB and CB with respect to (1) change in each of the five
VAS question during the time increment from 30 minutes to 180 minutes post-breakfast, (2) the
lunch cumulative energy intake in kcal (day1 + day 7) from fat, carbohydrate, protein and total
consumption, (3) changes in acylated ghrelin and PYY concentrations, respectively, across time
(0, 30. 60. 120 and 180 minutes post-breakfast) during day 1 and day 7 of EB and CB breakfasts,
and (4) change in acylated ghrelin and PYY concentrations, respectively, during the time
increment between 30 minutes and 180 minutes post-breakfast during day 1 and day 7. Statistical
analyses were all carried out using SAS® 9.2 (SAS Institute, Inc, Cary , NC 27513). Statistical
significance was declared for p ≤ 0.05.
Results
A total of 20 subjects completed the study [female (75%), African American (70%),
mean age 40.7 years, and mean BMI > 30 kg/m2 (Table2)].
Table 2. Baseline characteristics of participants on day 1 of each breakfast*
Group 1
Group 2
n
9
11
Male:Female
3:6
2:9
White:Black
2:7
4:7
Age, years
41.7±14.4
39.9±14.0
Weight, kg, EB
100.3±13.9
106.0±20.6
Weight, kg, CB
99.6±13.5
105.7±19.9
BMI, kg/m2, EB
35.7±2.8
39.4±9.3
BMI, kg/m2, CB
35.6±2.9
39.1±9.2
*
Age, weight, and BMI given as mean ± standard deviation
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Total Food and Energy Intake at Lunch
Subjects had a significantly lower cumulative lunchtime energy intake (kilocalories
consumed at lunch on days 1 and 7) during the EB week (p=0.05; Figure 1). The difference
between the two breakfasts in food and energy intake was not significant individually on day 1 or
day 7. Although the differences were not statistically significant, subjects consumed fewer
calories from carbohydrate and protein (p=0.06; Figure 1) during the EB test week.
1400
Energy intake (kcal)

1200

*

1000
800
600

Egg

400

Cereal

200
0
Total

Fat

CHO

Protein

Source of energy intake at lunch (day 1 + day 7)

Figure 1. Cumulative total energy intake (kcal) at lunch (p=0.05) and energy intake from fat,
carbohydrate, and protein in egg breakfast versus cereal breakfast.
Hunger and Satiety Following Breakfast
To measure the acute effect of each breakfast, the difference between VAS scores at 30
and 180 minutes post-breakfast was determined (Table 3). After consuming the EB on day 1,
subjects felt significantly less hungry before eating lunch than on day 1 of the CB (p=0.002). The
EB also induced a greater feeling of fullness before eating lunch compared to the CB on day 1
(p=0.02) and day 7 (p=0.02). The EB resulted in a decreased desire to eat before lunch on day 1
(p=0.03), and on day 7, subjects felt they could not eat much food at lunchtime (p=0.03).
Although there was no difference in hunger at 180 minutes following the EB on day 1 or day 7,
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the CB increased hunger scores on day 7. The EB did not significantly affect hunger, fullness,
desire to eat, or satisfaction after lunch was consumed.
Table 3. Acute effect of egg and cereal breakfasts on change in VAS score from 30 minutes postbreakfast and 180 minutes post-breakfast between day 1 and day 7
VAS Question
Day 1
Day 7
p-value
p-value
1
How hungry do you feel at this moment?
0.002*
0.245
*
2
How full does your stomach feel at this moment?
0.048
0.019*
3
How strong is your desire to eat at this moment?
0.028*
0.173
4
How much food do you think you could eat at this moment?
0.213
0.029*
5
How satisfied do you feel at this moment?
0.409
0.077
*
Significance at p < 0.05

Satiety-Related Hormones, Glucose, and Insulin
High concentrations of acylated ghrelin, the active form of ghrelin, are associated with
hunger 92 and are typically high before a meal4. Accordingly, acylated ghrelin concentrations
were greatest before breakfast and decreased 30 minutes post-breakfast. Subsequently, acylated
ghrelin concentrations increased up to 180 minutes post-breakfast. Compared to the CB, acylated
ghrelin concentrations were significantly lower 180 minutes following the EB on day one
(p=0.005; Figure 2). To measure the acute effect of each breakfast, the difference between
ghrelin concentrations at 30 and 180 minutes post-breakfast was determined. On day one of the
EB, acylated ghrelin remained significantly reduced before lunch (p=0.03; Figure 3) but not on
day seven (Figure 4).
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Figure 2. Acylated ghrelin concentrations on day 1 of the egg and cereal breakfasts were
different at 180 minutes (p=0.005).

Figure 3. Acylated ghrelin concentrations on day 7 of the egg and cereal breakfasts were not
different.
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Figure 4. The rise in acylated ghrelin occurring from 30 minutes post-breakfast to 180 minutes
post-breakfast on days 1 and 7. The EB significantly decreased acylated ghrelin in day 1
(p=0.03) but not on day 7.
Higher concentrations of PYY are associated with satiety, and following a meal, PYY
concentrations typically increase4, 93 as they did in this study. PYY concentrations were lowest
before breakfast but increased post-breakfast and reached their peak after lunch on days 1 and 7
for both breakfasts. PYY concentrations were significantly greater during the EB week on day
one 120 minutes and 180 minutes (p=0.006 and p=0.001, respectively; Figure 5) post-breakfast
and on day seven 180 minutes post-breakfast (p=0.03; Figure 6). The difference between PYY
concentrations at 30 and 180 minutes post-breakfast were significantly increased before lunch on
day one and day seven of the EB (p<0.001 and p=0.005, respectively; Figure 7).
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Figure 5. PYY concentrations on day 1 of the egg and cereal breakfasts were different at 120
minutes (p=0.006) and 180 minutes (p=0.001).
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Figure 6. PYY concentrations on day 7 of the egg and cereal breakfasts were different at 180
minutes (p=0.03).
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Figure 7. The change in PYY occurring from 30 minutes post-breakfast to 180 minutes postbreakfast on day 1 and 7. The EB increased PYY significantly more than the CB on day 1
(p<0.001) and day 7 (p=0.005).
There were no significant differences in serum glucose, insulin, or leucine concentrations
between the EB and the CB. However, at the end of the EB week, subjects with leucine
concentrations in the top 50th percentile before breakfast had a significant improvement in their
HOMA index for insulin resistance in one week compared to subjects in the bottom 50th
percentile for leucine (p=0.03). Subjects in the top versus bottom 50th percentiles for leucine had
an average difference of -0.51±1.51 and 0.63±0.93, respectively, in their HOMA index on day 7
of the EB. This effect was not observed on day 7 of the CB week.

Discussion
Because adherence to a low calorie diet can be difficult to maintain over time, dietary
strategies that decrease hunger and increase satiety may promote compliance and enhance weight
loss37, 38. Eggs have a high satiety value21, and thus previous research hypothesized that
consuming an EB would increase satiety and reduce caloric intake at lunch compared to an
isocaloric bagel breakfast22. As hypothesized, egg intake at breakfast was associated with greater
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satiety and significantly lower energy intake during their subsequent meal and for all meals in
the next 24 hours22, 25. A follow-up study of longer duration compared the effects of the two
same breakfasts (an EB and a bagel breakfast matched for ED) on weight loss37. Compared to the
bagel breakfast, the EB significantly increased weight loss and reduced waist circumference in
individuals following a reduced calorie diet. However, the EB had no significant effect on weight
loss and waist circumference on individuals not following a reduced calorie diet; therefore,
including eggs as part of a daily breakfast appears to induce greater results to a weight loss
regimen.
Increased intake of protein, especially those of higher quality, enhances weight loss44, 46,
47, 49

. The satiating effect of eggs may possibly be due to the high quality of egg proteins which

are rich in leucine, a branched chain amino acid (BCAA) implicated in inducing satiety48, 49, 94.
Vander Wal et al matched the breakfasts for ED but not macronutrient composition22, 37 so the
protein quantity as well as the protein quality was slightly higher in the egg breakfasts in these
studies; therefore, it was unclear if eggs induce satiety due to the quantity or quality of protein.
To determine the satiating effect of an EB, the two breakfasts compared in this study were nearly
identical in ED and macronutrient composition and protein quantity but differed in the quality of
protein. The breakfasts included a primary source of protein from either eggs or wheat which
have PDCAA scores of 100 and 42, respectively,88 as well as differing leucine content of 8.5%
and 6.8%, respectively. Because the two breakfasts were nearly identical, the effect of the EB on
reducing lunchtime food intake was not as pronounced as previously observed22. Nevertheless,
the higher quality of egg protein appears to significantly affect satiety, lunchtime energy intake,
and satiety-related hormones.
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Previous research showed that when dieters consumed an EB daily, they lost significantly
more weight and display greater dietary restraint and reductions in hunger than bagel breakfast
eaters37. In contrast, cross-sectional data from NHANES III showed that individuals who
consumed RTE cereals and other types of wheat-based breakfasts had significantly lower BMIs
than those who consumed meat and eggs for breakfast40. Meat and egg breakfast eaters were also
shown to have the highest daily energy intake of all the breakfast groups included in the
analyses40. While a precise explanation for this discrepancy is unknown, a possible reason may
be that egg intake is a marker of other dietary indiscretions. For instance, males with the highest
egg intake reported greater daily energy intake, greater saturated fatty acid intake, and a 5-fold
greater consumption of bacon than males with the lowest egg intake although their BMIs were
similar95. Bacon intake correlated with egg intake in males (r=0.35) and females (r=0.21)95.
Greater weekly egg consumption was positively associated with a less healthful diet, and males
with greater egg consumption were more likely to consume whole milk, red meat, and bacon95.
Therefore, the positive association of eggs with BMI may be due to the accompanying foods
such as bacon that are associated with egg intake. If eggs are consumed without such high fathigh energy accompaniments, they may influence BMI differently. However, the present study
was not designed to test this hypothesis.
Diets high in protein appear to result in greater reductions in weight because protein
increases satiety and thermogenesis49, 96, reduces loss of lean body mass, promotes body fat loss,
and improves glycemic control49. Recently, studies showed no particular advantage of dietary
macronutrient composition, including greater protein intake in long-term weight loss or
maintenance19. However, this study did not consider protein quality.
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Whey, soy, and gluten proteins appear to be equally effective at reducing hunger by
mediating the endocrine response in the postprandial state97. A breakfast containing 25% whey
elicited the greatest response in glucagon-like peptide 1 (GLP-1) and insulin94 possibly because
it has the highest leucine content which increases protein quality47. High protein intake leads to
greater consumption of the BCAA leucine44, 49. Layman et al46 compared a moderate protein diet
and a high carbohydrate diet with different amounts of leucine (9.89±0.19 g and 5.39±0.10 g,
respectively) over a 10-week period. Subjects in the protein group lost more weight and body fat
but less lean body mass than the carbohydrate group although the differences were not
significant46. In the present study, although the EB contained three times the amount of leucine
than the CB (1.77 g and 0.48 g, respectively), no difference was found in serum leucine between
the EB and CB. The breakfasts may not have contained the amount of leucine needed to change
serum leucine concentrations in the fed state.
Leucine intake may influence metabolism in other ways as well. Leucine regulates
phosphorylation events in the insulin signaling cycle that ultimately leads to the activation of the
initiation complex and the promotion of protein synthesis49. Leucine also stimulates the pancreas
to release insulin and modulates the intracellular insulin signals occurring in skeletal muscle and
adipose tissue49. This suggests that leucine acts as a metabolic regulator, and through its actions
in insulin and glucose, can preserve lean muscle while reducing body fat. BCAA concentrations,
including leucine, are elevated in obesity98, and increased levels are correlated with insulin
resistance99 which suggests that leucine is a biomarker for abnormal carbohydrate metabolism.
Yet, leucine supplementation improves glycemic control87. While there were no differences in
the group mean for serum leucine, those in the top 50th percentile for serum leucine showed a
significant improvement in insulin resistance. Also those in the top 50th percentile for HOMA
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index (higher insulin resistance) had significantly higher serum leucine and showed an
improvement in HOMA index. These data suggest that while an EB may influence satiety via
leucine-independent pathways, EB/leucine may improve insulin resistance.
No differences were found between the top and bottom percentiles for serum leucine on
ghrelin or PYY (data not shown). On day 1 of the EB, the subjects’ decreased hunger was
reflected by the significant decrease in acylated ghrelin concentrations post-breakfast.
Consuming the EB significantly increased postprandial PYY concentrations up to 3 hours
following breakfast on both days 1 and 7 which suggests that eggs are more satiating than cereal
in spite of the fact that they contained the same amount of protein. Thus, protein quality may
have a greater effect on satiety than protein quantity.
This study had some limitations. The breakfasts were designed to resemble typical
breakfasts and inordinate manipulations to the ingredients were avoided. Consequentially,
although the two breakfasts were closely matched for ED and macronutrient composition, the
glycemic load for the EB and CB was 24 and 30.8, respectively. Although it is unlikely that
glycemic load is responsible for the differences in satiety, the contribution of this small
difference on the favorable effect of the EB on satiety is unknown. Similarly, the role, if any, of
different types of lipids or other protein sources, including animal proteins, is unknown. GLP-1,
an anorectic hormone secreted in response to dietary proteins, was not measured. A dose
response of satiety to egg quantity is also unknown. Future studies should examine whether
protein quantity and quality work synergistically together to reduce appetite.
In summary, this study matches the breakfasts for energy density and macronutrient
composition to compare the effect of protein quality on measures of satiety. Eggs appear to affect
satiety by decreasing acylated ghrelin and increasing PYY up to four hours following breakfast.
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These effects were seen despite the closely matched breakfasts. The protein quality does appear
to affect satiety although this effect may be independent of leucine. Although serum leucine
concentrations did not correlate with measures of satiety, they do appear to be associated with an
improvement in glycemic control following just one week of a daily EB. Therefore, due to the
superior quality of proteins, eggs may provide a useful adjunct in weight management because
they increase satiety. The satiating role of other foods with higher protein quality should be
determined. Developing strategies to use foods as appetite suppressants may have considerably
greater appeal compared to the use of anorectic drugs which may have several undesirable side
effects.
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CHAPTER 4
EARLY RESOLUTION OF TYPE 2 DIABETES SEEN AFTER ROUX-EN-Y GASTRIC
BYPASS AND VERTICAL SLEEVE GASTRECTOMY100
In 2007-2008, approximately 72.5 million adults in the United States were considered
obese. Data from the 2007-2008 National Health and Nutrition Examination Survey showed an
overall obesity prevalence of 33.8% and a combined overweight and obesity prevalence of
68.0%32. Compared with individuals with a normal body mass index (BMI) of 18.5–24.9 kg/m2,
individuals with a BMI of 30 kg/m2 or more increase their risk of obesity-related diseases101 such
as cardiovascular disease, hypertension, certain cancers, and type 2 diabetes (T2D)12.
More than 8% of the U.S. population is affected by diabetes102. T2D accounts for the
majority of diagnosed cases of diabetes in adults, whereas type 1 diabetes only accounts for
5%102. T2D can be treated with diet, oral hypoglycemics, or insulin therapy. Between 2007 and
2009, 58% of adults with diabetes reported taking oral hypoglycemic, 12% reported taking
insulin, and 14% reported taking insulin and oral hypoglycemic103. The average direct medical
costs of an individual diagnosed with diabetes are more than double those of an individual
without diabetes103. Typically, diet and other strategies such as behavioral modification and
exercise result in only limited weight loss, which is usually not maintained72.
Bariatric surgery is the most effective tool for substantial weight loss and long-term
weight maintenance in the obese population and far surpasses nonsurgical obesity treatments104.
For example, a lifestyle intervention program reported an initial weight loss of 8.6% at 1 year,
and at 4 years, the individuals maintained a weight loss of 4.7%15 compared with individuals
who underwent gastric bypass and had an average weight loss of 32% at 1–2 years and 25% at
10 years27. The laparoscopic technique for Roux-en-Y gastric bypass (RYGB) was introduced in
100
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the early 1990s68 and has become the most widely used bariatric operation72. Improvements in
glycemic control have been seen in RYGB patients postoperatively before substantial weight loss
has occurred29, 72. The vertical sleeve gastrectomy (VSG), a newer bariatric procedure than the
RYGB, was originally performed as the first step in a two-step procedure leading to either a
RYGB or a biliopancreatic diversion with a duodenal switch in superobese patients (see
Appendix B)12, 13, 70, 104, 105. However, several studies have indicated that the laparoscopic VSG
can act as a stand-alone procedure and be as effective as the RYGB in initiating weight loss and
resolving T2D70, 72, 104. The VSG has provided promising results as a primary operation15,
although nationwide it accounts for only 7.6% of bariatric operations106.
Several studies have compared the effect of the RYGB to the VSG in diabetes patients;
however, these had a maximum of 91 subjects and focused on follow-up data at 1 or more
years71, 73, 74, 104. One of the most remarkable features of the RYGB is rapid diabetes resolution
before significant weight loss29, 68. Only one of the studies comparing glucose metabolism
following RYGB and VSG in patients concentrated on the early postoperative period of 1–3
months; the study concluded that both operations led to improvements in glucose homeostasis,
but it only had 13 RYGB patients and 14 VSG patients72. The current study compared a much
larger group of diabetes subjects taking medications who were operated on by the same two
surgeons with over 120 patients in both surgical groups. Because there has been a focus on the
early resolution of diabetes prior to significant weight loss with both the RYGB and VSG, the
goal of this retrospective study was to compare the respective efficacy of the two surgeries in
resolving the need for hypoglycemic medication in the first 2 months postoperatively.
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Methods
Between 2002 and 2010, obese patients with T2D (n = 262) on hypoglycemic medication
underwent either the RYGB (n = 123) or the VSG (n = 139). All data were obtained from the
surgeons’ office and recorded retrospectively. The surgeon provided a timeline that requested the
patient return for follow-up visits at 2 weeks, 2 months, 6 months, and annually for 5 years;
however, according to the surgeons, many patients discontinue follow-up at 2 months if they do
not develop any complications.
Diabetes Medication
All preoperative medications were recorded for each patient. Follow-up data were used to
determine if the patient resumed, discontinued, or changed medications postoperatively. T2D
resolution was defined as no longer requiring diabetes medication following surgery. Because
routine fasting blood glucose measurements were not taken, improvement in T2D control was
defined as a reduction in the number of diabetes medications taken postoperatively. Combination
therapy was defined as taking both insulin and an oral hypoglycemic medication.
Complications
Every complication occurring during or following surgery for each patient was recorded.
The total number of complications was determined for the hospital stay and upon discharge for
both operations. RYGB patients had longer hospitalizations with more records of temperatures
and vital signs, routine urinalysis, and complete blood count, notation of cholelithiasis on
operative reports, and routine chest X-rays that were not routinely performed in VSG patients.
Thus, atelectasis, anemia, elevated blood pressure, fever, hematuria, and cholelithiasis were
removed from the analysis because they were more likely to be recorded as complications in the
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RYGB group compared with the VSG group. The remaining complications were separated into
major and minor categories based on the judgment of the surgeons. Once these adjustments were
made, the incidence of overall major and minor complications was determined. Table 4 lists all
major and minor complications included in the analyses.
Table 4. Complete List of Complications for Both Operations Used in the Data
Analyses
Major Complications
Minor Complications
• Gastrointestinal leak
• Gout
• Anastomotic stricture
• Nausea and vomiting
• Small bowel obstruction
• Dehydration
• Hernia
• Hypokalemia
• Small bowel incarceration
• Hematoma
• Gastrointestinal bleed
• Hyper/Hypoglycemia
• Hypotension
• Ileus
• Cardiac ectopy
• Anastomotic edema
• Bradycardia or Tachycardia
• Elevated hepatic transaminases
• Hypoxemia
• Gastroparesis
• Pneumonia
• Abdominal wall abscess
• Pneumothorax
• Malnutrition
• Pouch laceration
• Gastritis
• Azotemia
• Dumping syndrome
• Heart failure
• CO2 narcosis
• Ventricular bigeminy
• Pulmonary venous congestion
• Septicemia
• Shock
• Anastomotic ulcer
• Mesenteric venous thrombosis
• Hematemesis
• Peptic or Perforated ulcer
• Deep vein thrombosis
• Pulmonary embolus
• Adhesions
• Fistula
• Guillain-Barre syndrome
• Pancreatitis
• Small bowel intussusception
• Necrotic small bowel
• Perforation
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(Table 4 continued)
•
•
•

Omental torsion
Blind pouch syndrome
Death

Statistical Analysis
All data were analyzed using a χ2 distribution. A P value of < 0.05 was considered
statistically significant.
Results
Although patients were given a schedule to follow, many were noncompliant, and
therefore there was great variability in the timing of follow-up visits.
Demographics
Age, weight, and BMI are given as mean ± SD values (Table 5). Race was not recorded
for 49 RYGB patients and 30 VSG patients. There were no significant differences in the patient
demographics when comparing the two surgical groups.
Table 5. Pre-operative Characteristics of Study Population According to
Operation
Roux-en-Y Gastric
Vertical Sleeve
Bypass
Gastrectomy
n
123
139
Age, years
46.8±9.5 (18-65)
50.5±10.3 (18-73)
Weight, kg
137.0±26.5 (95.9-225.0) 131.3±29.0 (68.2-235.0)
BMI, kg/m2
48.7±8.1 (37-69.6)
45.8±9.0 (30.9-72.1)
Sex (% Female)
78.0
66.9
Race (%)
77.0
89.9
• White
21.6
7.3
• Black
1.4
1.8
• Hispanic
0
0.9
• Other
Data are mean ± SD values (range) as indicated.
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Table 5 continued
BMI, body mass index.

Change in Diabetes Medication Usage
Upon discharge, 95 of the 123 (77.2%) RYGB and 107 of the 139 (77.0%) VSG patients
had been taken off their diabetes medication. Seventeen of the 26 (65.4%) RYGB patients and 19
of the 32 (59.4%) VSG patients who remained on diabetes medication up to 8 weeks
postoperatively showed improvement in their diabetes control by reducing the number of
medications taken and were not significantly different. Two RYGB patients who were not taking
diabetes medication preoperatively began taking them postoperatively. Patients who reported
taking medications postoperatively either remained on the same therapy as preoperatively or
switched to another type of therapy (Table 6).
Table 6. Patients Reporting Diabetic Medication Use Post-Operatively
Roux-en-Y Gastric
Vertical Sleeve
Bypass
Gastrectomy
n
28a
32b
c
No Change
15 (53.6)
21 (67.7)
Combination Therapy
5 (17.8)
5 (16.1)
 Insulin
Combination Therapy
1 (3.6)
4 (13.0)
 Oral Agent
Oral Agent  Insulin
7 (25.0)
1 (3.2)
Data are number of patients (%).
P < 0.05 versus bypass versus sleeve for all rows (one-tailed t test).
a
Two patients who were not on pre-operative medications began taking them postoperatively. They are reported as no change.
b
One patient reported taking medication pre- and post-operatively but the chart
did not specify what kind of therapy; therefore, this patient’s data is unreported
and the percentages were found using n=31.
c
Indicates patient remained on same therapy (oral, insulin, or combination) postoperatively.
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Eight weeks postoperatively, follow-up data were available for 38 RYGB patients and 71
VSG patients. Approximately 79% (n = 30) of RYGB patients and 83% (n = 59) of VSG patients
remained off diabetes medication.
Incidence of Complications
The overall incidence of major and minor complications was 24.8% and 22.8%,
respectively, for RYGB patients and 3.6% and 6%, respectively, for VSG patients (P < 0.001).
The incidence of complications both perioperatively and after discharge is shown in Table 7.
Table 7. Number of Diabetic Individuals Who Experienced a Complication Due to
Surgery
Surgery [n (%)]
Major Complications
Minor Complications
Hospital/PeriAfter
Hospital/PeriAfter
a
b
c
operatively
Discharged
Discharge
operatively
Roux-en-Y
19 (9.4)
31 (15.3)
Gastric
Bypass
1 (0.6)
5 (3.0)
Vertical
Sleeve
Gastrectomy
abc
P < 0.001 for comparison of procedures.
d
P < 0.025 for comparison of procedures.

20 (9.9)

26 (12.9)

1 (0.6)

9 (5.4)

Discussion
Although diabetes medications help control blood glucose levels, they may not prevent
the progression of the disease process, which leads to microvascular complications including
retinopathy, nephropathy, and neuropathy. T2D may also lead to cardiovascular disease, which,
in the United States, accounts for the death of 70% of individuals with T2D68. Bariatric surgery
appears to be the best method to prevent the occurrence and progression of T2D29, 68.
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Although this study and the study by Peterli et al72 are the only studies to focus on the
early response of T2D to both RYGB and VSG, other studies have evaluated the later response
of T2D to these operations71, 73, 74, 104. Similar to this study’s results, some of these other studies
found that VSG has similar efficacy as that reported for T2D remission with RYGB70, 71. One
found that both RYGB and VSG had a resolution rate of approximately 85% in 91 patients at 12
months postoperatively70, and another showed no significant differences in T2DM between the
two surgeries at 1 and 2 years postoperatively in 90 patients71. Both surgeries appeared to result
in early, dramatic improvements in glycemic control that was maintained postoperatively72.
However, some studies still suggest that RYGB may lead to better T2DM resolution, possibly
because of the exclusion of the proximal small intestines from the stream of undigested chyme73.
For example, one study that compared T2D remission for both operations showed almost a
twofold higher remission in RYGB patients compared with VSG patients73. In contrast, another
study reported greater diabetes resolution in VSG patients compared with RYGB patients74.
Approximately 76% of VSG patients discontinued their diabetes pharmacologic treatment
compared with only 60% of RYGB patients74. Similarly, other studies report discontinuation of
diabetes medication in the majority of VSG patients13, 70.
A high preoperative BMI, a previous bariatric operation, and T2D have been shown to be
positive predictors for the occurrence of surgical complications105. Several case series have
reported complication rates less than 10% in VSG patients12, 105, 106. Similarly, our study showed
an overall complication rate of 9.6% in diabetes patients undergoing VSG. In contrast, RYGB
patients appear to be more at risk for postoperative complications. Schauer et al 68 found an
overall major complication rate of 13.6% and minor complication rate of 24.9% in 191 diabetes
patients undergoing RYGB. The current study showed a higher incidence of major complications
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in the RYGB group (24.7%), but the minor complication rate (22.8%) was similar to the results
of Schauer et al68. Major complications commonly reported include gastrointestinal leaks15, 29,
small bowel obstructions13, 68, and deep vein thromboses68. Minor complications commonly
reported include wound infection13, 29, 68, nausea and vomiting68, and ulcers68. The only death
reported in this review was a bypass patient with T2D who died less than 6 weeks
postoperatively because of a pulmonary embolism. Similarly, other studies have suggested low
mortality rates: Basso et al13 reported only two deaths in 300 cases, and Gan et al107 reported no
deaths in 378 cases. In spite of the risk of complications, bariatric surgery is associated with
decreased overall mortality compared with findings among obese individuals seeking
conventional treatment27.
Limitations of this study include missing demographic data, which may skew the means
for both operations. Another limitation is the lack of laboratory data showing pre- and
postoperative blood glucose and hemoglobin A1c levels to confirm improvement in blood
glucose control. Follow-up was marginal so long-term maintenance could not be determined.
Long-term complications such as osteoporosis and vitamin deficiencies are typically handled by
the patient’s primary care physician. Because these charts could not be accessed, long-term
complications were not recorded so that their prevalence would not be underestimated.
Conclusions
Bariatric surgery appears to be an effective treatment for diabetes. Both the RYGB and
VSG appear to give similar early resolution to diabetes prior to significant weight loss in more
than half of the operated patients. Many individuals who were unable to discontinue their
diabetes medications were able to reduce the number of medications. The risk of complications
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also appears to be relatively low, especially in VSG patients. This review supports prior evidence
that bariatric surgery is a very successful treatment for obese individuals with diabetes seeking
optimal glycemic control. Although our study has limited long-term follow-up, we focused on
the question of early diabetes resolution as measured by the ability to stop hypoglycemic
medication in a large group of community-operated patients. RYGB and VSG seem to have a
similar positive effect on the early resolution of diabetes; however, the rate of complications was
less with the VSG. Therefore, the VSG should be considered as a viable option for individuals
with T2D seeking weight loss surgery.
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CHAPTER 5
SLEEVE GASTRECTOMY RESULTS IN LESS WEIGHT LOSS BUT FEWER MAJOR
COMPLICATIONS THAN THE ROUX-EN-Y GASTRIC BYPASS
Data from the 2007-2008 National Health and Nutrition Examination Survey (NHANES)
was used to show that 33.8% of adults in the United States (US) are obese32. Bariatric surgery is
the most effective therapy for morbid obesity8, and its use has increased exponentially over the
past decade from approximately 13,400 surgeries in 1998108 to approximately 220,000 surgeries
in 2008109. However, only 1% of clinically eligible individuals are using bariatric surgery as a
treatment option for morbid obesity109. Data from the Bariatric Outcomes Longitudinal Database
(BOLD) demonstrated that the majority of individuals seeking bariatric surgery are adults 26-55
years of age (71.2%), females (78.8%), and white (78.1%), and more than half of these
individuals undergo the gastric bypass operation57. A newer bariatric operation, the vertical
sleeve gastrectomy (VSG), has emerged as a one-step procedure from the first step in creating
the biliopancreatic diversion with a duodenal switch13, 54 for super obese patients. Although the
VSG accounts for less than 5% of all bariatric procedures performed in the US57, 59, it appears to
be safe, results in adequate weight loss, and is gaining recognition as a suitable treatment for the
morbidly obese patient.
Bariatric surgery has been shown to result in more significant long-term weight loss
compared to non-operative methods such as diet and exercise15, 27, 28, 56, 67. The average body
mass index (BMI) for individuals electing to have bariatric surgery is greater than 40 kg/m2 61, 62,
76

. Bariatric surgery results in substantial weight loss and improvement or resolution of co-

morbid conditions31, 76 but can be accompanied by complications. The incidence of
complications associated with the Roux-en-Y gastric bypass (RYGB) and the VSG is low3, 53
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which may be due in part to a growth in the experience of surgeons and the introduction of
laparoscopic techniques8, 28, 110.
Many of the bariatric surgical series have been reported from academic centers14, 57, 59,
but as the number of bariatric surgeries performed annually continues to rise, community
surgeons are performing the operations more frequently. The community surgeon meets with the
patient pre-operatively and for several weeks post-operatively. If a patient does not encounter an
early serious surgery-related complication, the patient may seek follow-up with their family
physician after the first six weeks of the post-operative period for continued care. Although there
are guidelines for the pre- and post-operative care of bariatric patients111, 112, family physicians
should also understand the bariatric operations used, their potential for weight loss, improvement
of co-morbid conditions, and the associated surgical complications occurring in the initial postoperative period. The objective of this report is to compare the weight loss and early surgical
complications in more than 1600 patients who underwent either the RYGB or the VSG in a
private community surgical practice.
Methods
This study was exempted by the institutional review board at Pennington Biomedical
Research Center.
Subjects
We conducted a retrospective chart review of 835 RYGB patients and 766 VSG patients
who underwent their operation between 2002 and 2010 by two surgeons in a private community
surgical practice. All of the patients met the eligibility criteria for bariatric surgery as defined by
the National Institutes of Health35. The patients were divided into either insured or self-pay
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categories based upon information provided in the chart. We hypothesized that self-pay patients
would lose more weight based on their greater personal financial investment in the procedure and
maintain better long-term weight loss than individuals who had insurance reimbursement.
Because some demographic data were missing, the missing data were subtracted from the group
total and the new totals were used to compute percentages for age, sex, race, and insurance
coverage.
Weight Loss
Each patient’s weight on the day before or the day of surgery was documented as the
patient’s baseline weight. Post-operative weights were recorded at the weekly time points on
which they were obtained for up to two years. The patients’ weights between 26-52 weeks and
78-104 weeks were compared to their baseline weight to determine the percentage of total body
weight lost at one and two years. The weight loss in insured and self-pay patients in both surgical
groups was also compared.
Complications
Any event occurring during surgery or within the first six weeks post-operatively was
recorded for every patient for both operations. The recorded complications were divided into
minor and major categories in consultation with the operating surgeons following the guidelines
of the American Society for Metabolic and Bariatric Surgery3. The surgical complications in
insured and self-pay patients in both surgical groups were also compared.
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Statistical Analyses
A Student’s t-Test was used to determine differences in normally distributed data. The χ2
distribution was used to determine differences in categorical data. Significance was defined as α
< 0.05.
Results
Age, gender, race, pre-operative weight, pre-operative BMI, and insurance coverage were
recorded if available in the patient’s chart (Table 8). On average, VSG patients were
approximately three years older than RYGB patients. Significantly more white individuals
underwent surgery than blacks (p=0.025) or Hispanics and other ethnicities (p=0.015).
Significantly more females underwent surgery than males (p=0.004). Baseline weight and
baseline BMI were different between the two surgical groups (p<0.001).
Table 8. Pre-Operative Demographic Characteristics of Patients in Each Surgical Group

Age, years
Weight, kg
BMI, kg/m2
Gender (%)
Male
Female
Race (%)
White
Black
Hispanic
Other
Insurance coverage (%)
Insured
Self-pay

Roux-en-Y Gastric
Bypass
n=829
39.6±10.4 (16-68)
n=805
134.2±27.8
n=805
47.9±8.1
n=832
17.4
82.6
n=523
76.5
19.7
3.1
0.8
n=688
90.0
10.0
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Vertical Sleeve
Gastrectomy
n=764
43.1±11.4 (15-73)
n=761
126.6±29.7
n=761
45.1±8.9
n=766
18.5
81.5
n=577
88.4
8.8
1.7
1.0
n=742
8.2
91.8

P-value
<0.001
<0.001
<0.001
0.004

0.025
0.015
0.015
<0.001

Table 8 continued
Age is presented as the mean ± standard deviation (range).
Weight and BMI are presented as mea n± standard deviation.

Weight Loss
There was a significant difference in the percentage of initial weight lost between the
RYGB and VSG surgical groups at one (p<0.001) and two years (p<0.001; Figure 8). At one
year, RYGB patients (n=158) lost 36.4% and VSG patients (n=242) lost 29% of their baseline
body weight. At two years, RYGB patients (n=39) lost 42.7% whereas VSG patients (n=135)
lost 30.3% of their baseline body weight.

0.0

Total body weight loss (%)

-5.0

0-4

5-12

13-26

27-52

53-78

79-104

-10.0
-15.0
-20.0
Bypass
-25.0

Sleeve

-30.0
-35.0
-40.0
-45.0

*
*

Time (weeks)

Figure 8. The Roux-en-Y gastric bypass results in greater weight loss at one and two years
(p<0.001 for both).
There were no differences in weight loss between self-pay and insured RYGB and VSG
patients (Table 9). Self-pay patients in both surgical groups continued to lose weight up to two
years. Self-pay VSG patients lost 31% more weight at two years than insured VSG patients, but
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this difference was not statistically significant. RYGB patients with insurance coverage
continued to lose weight up to two years, but insured VSG patients re-gained almost 8% of their
weight at two years.
Table 9. Percentage of Weight Loss between the Roux-en-Y Gastric Bypass and the Vertical
Sleeve Gastrectomy at 1 and 2 Years Based upon Payment Methoda
Roux-en-Y Gastric Bypass
Vertical Sleeve Gastrectomy
1 year

2 years

1 year

2 years

Insurance

36.7±9.7

45.6±23.4

27.7±10.5

19.8±29.0

Self-pay

34.0±8.0

41.9±27.4

27.0±9.3

28.7±23.5

a

Mean ± standard deviation

Complications
RYGB patients experienced a significantly higher incidence of complications than VSG
patients (p<0.001). During the peri-operative period in the hospital, 20.4% (n=170) of RYGB
patients and 1.0% (n=8) of VSG patients experienced a complication. In the first six weeks postoperatively, 15.4% (n=129) of RYGB patients and 4.2% (n=32) of VSG patients experienced a
complication. RYGB patients experienced a greater number of the following major
complications than VSG patients: stricture (p<0.001), gastrointestinal bleed (p<0.001), small
bowel obstruction (p<0.025), and cardiopulmonary complications (p<0.001). The incidence of
gastrointestinal leaks and thromboembolic complications was not different in the RYGB and
VSG operations (Table 10). There were no differences in surgical complications between insured
and self-pay patients for either operation.
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Table 10. Incidence of Major Complications among Total Population*
Roux-en-Y Gastric Bypass
Vertical Sleeve Gastrectomy
Stricture1
26 (3.1)
2 (0.3)
1
Gastrointestinal Bleed
25 (3.0)
1 (0.1)
Gastrointestinal Leak
4 (0.5)
0 (0)
Small Bowel Obstruction2
9 (1.1)
0 (0)
Cardiopulmonary1
19 (2.3)
2 (0.3)
Thromboembolic
1 (0.1)
3 (0.4)
*
n (%)
1
p<0.001
2
p<0.025

Discussion
Bariatric surgery is the most effective treatment for morbid obesity because it
significantly reduces body weight, sustains weight loss, and improves co-morbidities associated
with obesity to a greater extent than non-surgical treatments8, 113, 114. Individuals typically seek a
weight loss operation when other treatment options such as diet, exercise, and behavioral
modifications fail to produce substantial or durable weight loss8, 114. Obesity decreases life
expectancy28, but undergoing bariatric surgery can decrease the risk of mortality in the morbidly
obese by 35% compared to non-operated controls14, 15. This increase in life expectancy appears to
be due to the improvement or resolution in obesity-related co-morbidities such as type 2
diabetes, certain cancers, and heart disease61, 115.
Lifestyle modification programs report only modest weight loss usually followed by
weight regain27, and pharmacologic therapies such as orlistat and phentermine produce a weight
loss of only 2.9-3.6 kilograms after one year27, 50, 116. The RYGB has been reported to result in
maximum total body weight loss of 32% at one to two years15. Surgical journals express weight
loss as a percent of excess weight loss [(weight loss/excess weight)*100 where excess weight is
baseline weight minus ideal weight as defined by the 1983 Metropolitan Life Insurance Tables
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for a medium frame]. The RYGB has been shown to result in excess weight losses of 70% at two
years, 58% at 5 years, and 55% after ten years29. Our retrospective review showed greater total
body weight loss at one and two years for RYGB patients, and the VSG patients in our study lost
an amount of weight similar to that previously reported for the RYGB15, 117. Mean percent excess
weight loss reported for VSG patients ranges from 49-62% at one year62, 63, 65 and up to 68% at
two years64. The VSG results in considerable excess weight loss at one year in obese patients
with lower BMIs54 and has been favored by surgeons in high-risk populations118. Although some
weight regain occurs, the excess weight loss exceeds the results of non-surgical treatment
options.
This study showed a drastic gap in insurance coverage between the RYGB and VSG
surgical groups. Because the RYGB is a more established operation, the percentage of
individuals undergoing the RYGB covered by insurance was much greater than the newer VSG.
A review of over 66,000 bariatric surgeries between 2005 and 2007 in the US found that ~87%
of individuals had private or some other form of insurance whereas almost 6% were uninsured59;
however, the effect of insurance coverage on weight loss was not discussed. We hypothesized
that individuals who paid for their operation would lose more weight than individuals who were
covered by insurance. Although there was no statistical difference in weight loss between selfpay and insured patients, self-pay VSG patients had numerically greater weight loss than insured
VSG patients at two years. There was no weight loss advantage to self-pay patients in the
RYGB group.
Common minor complications identified by the American Society for Metabolic and
Bariatric Surgery (ASMBS) include atelectasis, dehydration, diarrhea, dumping syndrome,
esophageal reflux, pneumonia, nausea and vomiting, and infection. Common major
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complications include cardiopulmonary issues such as cardiac arrest, deep venous thrombosis,
pulmonary embolism and respiratory arrest or failure, gastrointestinal (GI) bleeds or leaks, small
bowel obstruction, anastomotic stricture, ulcer at the anastomosis or in the GI tract, and wound
dehiscence or infection.
The most common of these complications experienced by patients appears to be
dependent on the type of surgery and their surgeon’s experience. Similar to our study,
Carrodeguas et al84 found anastomotic strictures to be the most commonly experienced
complication (7.3%) among the 1300 RYGB patients. Gastrointestinal bleeds and
cardiopulmonary-related problems were the other top reported complications among RYGB
patients in our study. Less than 5% of VSG patients from our study experienced a complication
in the first six weeks of the post-operative period. The top three reported complications in the
VSG group were thromboembolic-related, strictures, and cardiopulmonary-related adverse
events. In contrast, other studies report slightly higher overall VSG complication rates ranging
between 5-9% with the most commonly reported complications being GI bleeds and GI leaks12,
13

. The success of the surgeons in reducing gastrointestinal leaks in our study may be attributable

to the operative technique they utilized and have previously published53.
Studies have shown low overall mortality rates following bariatric surgery ranging from
0.1% to 1.5%57, 59, 77. Thirty-day mortality rates appeared to be less than 0.2% for all types of
bariatric surgery and less than 2% specifically for RYGB. The mortality rate for VSG appears to
be less than 1%12, 13, 79. According to data of over 66,000 surgeries from ASMBS Centers of
Excellence, the three predominant causes of mortality were pulmonary emboli, cardiac
complications, and sepsis/infection59. In our study, two deaths occurred during the initial post-
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operative period: one RYGB patient and one VSG patient each died due to a pulmonary
embolism.
The limitation of this study was the short duration of follow-up for the majority of
patients although the surgeons encourage their patients to adhere to a five-year follow-up
regimen. It appeared that the long-term follow up care after the initial six-week post-operative
period was performed by the patients’ family physician. Our study is one of the first comparative
studies with a large number of sleeve gastrectomy patients. The weight loss reported for VSG
patients in this study is similar to weight loss reported in previous RYGB studies. Therefore, we
feel that the VSG is a viable option for obese patients seeking weight loss surgery. The incidence
of complications was much lower in the VSG surgical group, a finding which will hopefully
encourage a greater acceptance of bariatric surgery by insurance providers and family
physicians. The low mortality rates following bariatric surgery reported in our study and several
other studies are evidence that the operations are growing safer as the techniques become more
standardized. Overall, bariatric surgical risks appear to be low. Therefore, when conventional
treatments for weight loss have failed, obese individuals and their family physicians should
consider bariatric surgery in their weight loss discussions. Now that family physicians are
becoming more involved in the pre- and post-operative care of bariatric surgery patients, the
patients may seek advice from them on surgery selection. Additionally, the VSG should be
regarded as an alternative to the RYGB because it is becoming more widely used throughout the
US, results in significant weight loss, and is associated with a lower rate of complications.
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CHAPTER 6
SUMMARY
These three studies have evaluated two of the most commonly used treatment alternatives
to combat obesity. An egg breakfast can decrease hunger and enhance feelings of fullness
because eggs contain high quality protein. Because consuming an egg breakfast daily increases
satiety, individuals following a diet should be encouraged to try this strategy to further promote
weight loss. If weight loss cannot be achieved through diet, exercise, or behavioral modification,
bariatric surgery is the most effective treatment for obesity. Two bariatric operations, the RYGB
and the VSG, both improved or resolved T2D in the early post-operative period in a large
percentage of patients. The surgeries also resulted in significant weight loss at one and two years.
Complication rates and mortality appear to be low, especially in VSG patients. Therefore,
bariatric surgery appears to be a safe, effective tool for weight loss and co-morbidity
improvement or resolution.
One randomized trial examining 811 overweight and obese adults following different,
calorie-restricted diets up to two years showed that no specific macronutrient composition diet
led to greater weight loss than another19. The different diets led to similar results because they all
restricted daily caloric consumption19. However, maintaining a long-term, calorie-restricted diet
can be difficult so dietary strategies that increase satiety may be effective tools. Previous
research has shown that a breakfast containing protein decreases hunger23 and increases satiety45,
but no study has investigated the effect of protein quantity compared to protein quality. Eggs
contain the BCAA leucine which increases the protein quality. Despite the fact that the EB was
matched with an isocaloric RTE CB for ED and macronutrient composition, the EB led to
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significantly lower concentrations of acylated ghrelin and higher concentrations of PYY than the
CB and these effects appear to be independent of leucine.
However, individuals with higher serum leucine concentrations displayed greater
improvements in their HOMA index for insulin resistance in just one week. Thus, individuals
with insulin resistance may benefit from consuming a daily EB because it may potentially
prevent the progression to T2D. Individuals who have already been diagnosed with T2D may
gain the greatest control through bariatric surgery. Patients who underwent the RYGB returned
to normal blood glucose levels before significant weight loss occurred29. More than 75% of
RYGB and VSG patients were able to eliminate the need for medication in the early postoperative period. More than half were able to remain off medication at eight weeks postoperatively. Thus, these studies are informative in regard to the prevention and treatment of T2D.
Neither breakfast resulted in a decrease in energy intake or body weight at the end of the
test week; however, the breakfast study was short in duration, and weight loss is likely if
individuals consume eggs for breakfast for a longer duration of time in addition to energy
restriction37. In contrast, bariatric surgery has been shown to produce significant weight loss that
can be sustained over time29, 66. The RYGB produced significantly greater weight loss than the
VSG at one and two years, but all patients continued to lose weight up to two years postoperatively regardless of the type of operation. Self-pay patients who underwent either operation
did not lose more weight than insured patients. Although the RYGB resulted in greater weight
loss, it also led to more overall and major complications than the VSG. Mortality from either
operation was less than 0.3%.
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These studies had several limitations. In the breakfast study, the EB and CB were not
matched for other factors that influence satiety such as glycemic index, and the contribution of
such factors to the results cannot be accounted for in the study. Also, GLP-1, an anorectic
hormone known to increase satiety following a meal, was not measured. The short duration of
the study precluded the evaluation of the effect of protein quality on weight loss. The marginal
long-term follow-up was the biggest limitation of the bariatric surgery retrospective chart review,
but it reflects the reality of a community surgical practice where many patients discontinue care
with the surgeon if no major complications arise during the early post-operative period. A greater
number of individuals with follow-up two or more years post-operatively would more accurately
illustrate the differences between the RYGB and the VSG. The charts also lacked laboratory data
that would have provided information on glucose and insulin concentrations, HbA1c levels, lipid
profiles, blood pressures, and vitamin levels in bariatric patients. Because the study examining
diabetes improvement and resolution lacked these data, diabetes improvement and resolution had
was defined as a decrease in the number of hypoglycemic medications taken or the
discontinuation of medications taken, respectively.
Future studies pertaining to breakfast consumption should continue to examine the effects
of high protein quality on hunger, satiety, and energy intake. The roles of leucine and GLP-1
remain to be examined. Future studies that focus on the effects of bariatric surgery on type 2
diabetes should try to explore the mechanisms involved in the quick improvement seen in blood
glucose levels before significant weight loss occurs. The low prevalence of gastrointestinal leaks
in the VSG suggest that the surgeon’s previously published technique should be more widely
adopted53.
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This thesis contributes to the peer-reviewed literature. First, it demonstrates the role of
protein quality in controlling hunger and satiety. Secondly, the bariatric surgery studies are two
of the first studies comparing a large group of RYGB and VSG patients and their difference in
weight loss, complications, and ability to improve and resolve T2D.
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APPENDIX B
SLEEVE GASTRECTOMY SURGICAL TECHNIQUE
The sleeve gastrectomy has been recognized as a viable bariatric surgical procedure in
selected patients since 2007.119 The sleeve gastrectomy is commonly performed via the
laparoscopic approach. The greater curvature of the stomach is devascularized, and a sizing
dilator is inserted within the stomach and positioned medially along the lesser curve. Using the
dilator as a “template,” the antrum, body, and fundus of the stomach lateral to the dilator is
resected and removed, leaving a tubular stomach of approximately 90–120 mL in volume. This
surgical technique has minimized the risk of gastrointestinal leaks.53
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